Longer-lasting psoriasis shots, still unproven
- Oruka has no approved products yet, so the stock rests on clinical trial data and cash runway.
- ORKA-001 hit 63.5% PASI 100 at Week 16 in a Phase 2a psoriasis trial.
- Cash was $496.0 million on March 31, 2026, before a $700.4 million gross public offering in April 2026.
- ORKA-002 showed a roughly 75 to 80 day half-life in Phase 1, supporting less frequent dosing if efficacy holds up.
- The main risk is simple: big immunology players already sell strong psoriasis drugs.
A better dosing bet
Oruka is trying to improve proven immunology drug ideas, not invent a brand-new disease pathway from scratch. Its lead drug, ORKA-001, targets IL-23p19, a known psoriasis pathway. The pitch is that antibody engineering can make the drug last longer in the body, which could mean fewer shots for patients.
The bull case got stronger in 2026. ORKA-001 reported a 63.5% PASI 100 response at Week 16 in the Phase 2a EVERLAST-A trial, meaning 40 of 63 patients had complete skin clearance by that score. Earlier data also showed an approximately 100 day half-life and sustained IL-23 pathway activity through 24 weeks in a lab assay.
The balance sheet is unusually large for a clinical-stage biotech. Oruka had $496.0 million in cash, cash equivalents, and marketable securities on March 31, 2026. In April 2026, it raised another $700.4 million in gross proceeds before fees and expenses.
The bear case is that this is still a pre-commercial company in a crowded field. Psoriasis already has effective branded drugs from larger companies. Oruka must show that longer dosing, strong skin clearance, safety, and real-world use can matter enough to win share.
Cash today, approvals later
Oruka does not yet make money from selling medicine. It spends investor capital on research, clinical trials, manufacturing work, and regulatory preparation. If a drug is approved, the company could sell it itself, partner it, or license it, but none of that has happened yet.
The company came together through the merger of ARCA biopharma and Oruka Therapeutics in 2024. The combined company now focuses on inflammatory and immunology diseases, especially inflammatory dermatology. Legacy ARCA assets are being divested rather than driving the story.
This model can create high upside because one successful biologic can be very valuable. It can also break fast. A failed trial, a safety signal, a manufacturing delay, or a tougher-than-expected regulator can cut the value of the pipeline before any revenue arrives.
The pipeline that matters
ORKA-001
ORKA-001 is an IL-23p19 antibody in Phase 2 trials for moderate-to-severe psoriasis. It is the lead program, with EVERLAST-A Week 28 and 52-week data expected in the second half of 2026.
ORKA-002
ORKA-002 is an IL-17A/F antibody that moved into the ORCA-SURGE Phase 2 psoriasis trial in February 2026. Phase 1 data showed an approximately 75 to 80 day half-life.
ORKA-021
ORKA-021 is the planned sequential use of ORKA-002 followed by ORKA-001. The idea is to pair faster IL-17 response with longer IL-23 maintenance.
ORKA-003
ORKA-003 is a third monoclonal antibody program for an undisclosed inflammatory dermatology pathway. It gives Oruka another shot on goal, but details are still limited.
Legacy ARCA assets
The old ARCA clinical assets are not the core business anymore and are being divested. Investors should not treat them as the main value driver.
One pre-revenue segment
Oruka reports as a single pre-commercial biotechnology business after the ARCA merger. The latest filed updates describe operations as research and clinical development, with no commercial product revenue disclosed.
What could break
Phase 2 data fade
High impact · Medium oddsORKA-001 cleared an important Week 16 hurdle, but psoriasis drugs must keep working over time. If Week 28 or 52-week data show lower skin clearance, safety issues, or weaker dosing durability, the longer-lasting story loses force.
Crowded psoriasis market
High impact · High oddsOruka is going after markets where large drug companies already sell trusted products. A new drug may need better clearance, fewer injections, strong safety, or better pricing to matter. Good trial data may not be enough if doctors see little reason to switch.
ORKA-002 execution risk
Medium impact · Medium oddsORKA-002 showed a long half-life in healthy volunteers, but that does not prove it will work well in patients. The Phase 2 ORCA-SURGE trial must show efficacy, safety, and a dosing profile that stands out against existing IL-17 drugs.
Supply chain and BIOSECURE risk
Medium impact · Medium oddsOruka relies on foreign contract manufacturers, including WuXi Biologics. The company said WuXi has not been automatically designated under the enacted BIOSECURE Act, but future designation could disrupt manufacturing plans or force supplier changes.
No product revenue
High impact · High oddsOruka has a large cash balance, but it still has no approved medicine and no commercial product sales. Clinical trials are expensive, and later-stage programs can cost much more than early studies. If timelines stretch, the company may need more capital later.
In one breath
What does Oruka Therapeutics do?
Oruka develops antibody drugs for inflammatory skin diseases, starting with psoriasis. Its main goal is to make drugs that work well and can be dosed less often.
Does Oruka have any approved drugs?
No. Oruka is a clinical-stage biotech, which means its drugs are still being tested and are not approved for sale.
Why did ORKA rise in importance in 2026?
The key change was ORKA-001's Week 16 EVERLAST-A data, where 63.5% of patients reached PASI 100. The company also raised $700.4 million in gross proceeds in April 2026.
What are the next major ORKA catalysts?
The next watched events are ORKA-001 EVERLAST-A Week 28 and 52-week data in the second half of 2026. Investors are also watching ORKA-002's hidradenitis suppurativa Phase 2 start and 2027 data from EVERLAST-B and ORCA-SURGE.